Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was Active, not recruiting
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: December 22, 2004
Last updated: October 23, 2007
Last verified: March 2005
The purpose of this study is to assess potential interactions between intravenous (IV) cocaine and 3 doses of GBR 12909.
Drug: GBR 12909
||Primary Purpose: Treatment
||Study of Interactions Between GBR 12909 and Cocaine
Primary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
This is Phase 1, double-blind, placebo-controlled human laboratory clinical pharmacology study that will assess the potential interactions between IV cocaine and 3 escalating oral doses of GBR 12909. The primary objective is to determine safety of GBR 12909 administration and if there are significant interactions between GBR 12909 treatment concurrent with IV cocaine infusions.
|Ages Eligible for Study:
||18 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Must be within 20% ideal body weight and must weigh at least 45 kg.
- Must understand the study procedures and provide written informed consent.
- Must meet DSM-4 criteria and are non-treatment seeking at time of study.
- Please contact study site for more information
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00100113
|U of Texas Medical Branch Galveston
|Galveston, Texas, United States, 77555 1031 |
||Kathryn Cunningham, Ph.D.
||University of Texas Medical Branch - Galveston
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 22, 2004
||October 23, 2007
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 30, 2015
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs